Efficacy of apremilast in the treatment of moderate to severe psoriasis: a randomised controlled trial. (Q48421921)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22748702%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

title

Efficacy of apremilast in the treatment of moderate to severe psoriasis: a randomised controlled trial (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22748702%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22748702%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

author name string

Jennifer C Cather

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22748702%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

Les Rosoph

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22748702%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

Howard Sofen

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22748702%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

Richard G Langley

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22748702%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

Robert T Matheson

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22748702%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

ChiaChi Hu

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22748702%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

Robert M Day

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22748702%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

language of work or name

English

0 references

publication date

29 June 2012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22748702%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22748702%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

volume

380

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22748702%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

issue

9843

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22748702%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

page(s)

738-746

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22748702%20AND%20SRC:MED&resulttype=core&format=json

High prevalence of potential drug-drug interactions for psoriasis patients prescribed methotrexate or cyclosporine for psoriasis: associated clinical and economic outcomes in real-world practice

6 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960642-4

7 January 2021

A systematic review and meta-analysis of efficacy and toxicity of disease modifying anti-rheumatic drugs and biological agents for psoriatic arthritis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960642-4

7 January 2021

Adherence to treatment in patients with psoriasis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960642-4

7 January 2021

Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960642-4

7 January 2021

Long-term safety and efficacy of 50 mg of etanercept twice weekly in patients with psoriasis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960642-4

7 January 2021

Tolerability and safety of biological therapies for psoriasis in daily clinical practice: a study of 103 Italian patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960642-4

7 January 2021

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960642-4

1 reference

7 January 2021

Localized effects of cAMP mediated by distinct routes of protein kinase A.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960642-4

7 January 2021

Keynote review: phosphodiesterase-4 as a therapeutic target

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960642-4

7 January 2021

Apremilast, a cAMP phosphodiesterase-4 inhibitor, demonstrates anti-inflammatory activity in vitro and in a model of psoriasis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960642-4

7 January 2021

Apremilast, a novel PDE4 inhibitor, inhibits spontaneous production of tumour necrosis factor-alpha from human rheumatoid synovial cells and ameliorates experimental arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960642-4

7 January 2021

Phosphodiesterase 4 inhibitors reduce human dendritic cell inflammatory cytokine production and Th1-polarizing capacity

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960642-4

7 January 2021

Differential expression and function of phosphodiesterase 4 (PDE4) subtypes in human primary CD4+ T cells: predominant role of PDE4D

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960642-4

7 January 2021

Phosphodiesterase isoenzyme families in human osteoarthritis chondrocytes--functional importance of phosphodiesterase 4.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960642-4

7 January 2021

An open-label, single-arm pilot study in patients with severe plaque-type psoriasis treated with an oral anti-inflammatory agent, apremilast.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960642-4

7 January 2021

Dermatology Life Quality Index (DLQI)--a simple practical measure for routine clinical use.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960642-4

7 January 2021

The impact of pruritus on quality of life: the skin equivalent of pain.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960642-4

7 January 2021

10.1016/S0140-6736(12)60642-4

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22748702%20AND%20SRC:MED&resulttype=core&format=json

release_jmqymybwxjcjvjgzoaspnpp2ca

6 February 2020

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/jmqymybwxjcjvjgzoaspnpp2ca

24 November 2022

mapped directly with Wikidata item

1 reference